FindTrial
Sign In

evorpacept

DRUG12 trials

Sponsors

Alx Oncology Inc., Sanofi-Aventis Recherche & Developpement, Alx Oncology Holdings Inc., ALX Oncology Inc., Sanofi

Conditions

AML, AdultAcute Myeloid LeukemiaBladder CancerBreast CancerCancerHER2-expressing CancersHead and Neck CancerHead and Neck Squamous Cell Carcinoma

Phase 1

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
TerminatedNCT04417517
ALX Oncology Inc.Higher Risk Myelodysplastic Syndromes
Start: 2020-10-02End: 2025-06-10Updated: 2025-07-20
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
RecruitingNCT04643002
SanofiPlasma Cell Myeloma Refractory
Start: 2021-01-25End: 2028-04-20Target: 258Updated: 2026-03-30
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
TerminatedNCT04755244
ALX Oncology Inc.Acute Myeloid Leukemia, AML, Adult
Start: 2021-05-05End: 2023-08-16Updated: 2024-11-27
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
CompletedNCT05027139
Jazz PharmaceuticalsHER2-expressing Cancers
Start: 2021-09-15End: 2025-09-30Updated: 2025-10-16
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
CompletedNCT05524545
ALX Oncology Inc.Bladder Cancer, Urothelial Carcinoma
Start: 2022-11-02End: 2025-06-27Updated: 2025-07-25
Phase 1/2 trial evaluating isatuximab in combination with evorpacept and dexamethasone in relapsed or refractory multiple myeloma (RRMM)
RecruitingCTIS2024-514993-38-00
Sanofi-Aventis Recherche & DeveloppementCancer
Start: 2021-03-31Target: 19Updated: 2026-01-23

Phase 2

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Active, not recruitingNCT04675294
ALX Oncology Inc.Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Start: 2021-04-02End: 2026-06-30Updated: 2025-08-01
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Active, not recruitingNCT04675333
ALX Oncology Inc.Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Start: 2021-05-10End: 2026-06-30Updated: 2025-08-03
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
RecruitingNCT05787639
University of California, San DiegoOropharynx Cancer
Start: 2024-02-20End: 2028-05-30Target: 29Updated: 2025-06-25
A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Active, not recruitingCTIS2023-509406-30-00
Alx Oncology Inc.Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
Start: 2022-01-24Target: 87Updated: 2026-01-22
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-03)
Active, not recruitingCTIS2023-508340-22-00
Alx Oncology Inc.metastatic or unresectable, recurrent HNSCC
Start: 2021-08-11Target: 50Updated: 2026-01-23
Master Protocol: A Phase 1b / 2, Multicenter, Multi Arm Study of Evorpacept in Combination with Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09) Substudy Protocol: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer (ASPEN-09-03)
Not yet recruitingCTIS2025-522012-16-00
Alx Oncology Holdings Inc.Breast Cancer
Target: 36Updated: 2026-01-23

Related Papers

Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.
2026-03-23
Abstract PS8-09: Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study
Clinical Cancer Research2025-06-131 citations
Neoadjuvant SBRT followed by evorpacept and pembrolizumab in HPV-mediated head and neck squamous cell carcinoma: Investigation of pathologic response.
Journal of Clinical Oncology2025-05-28
The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments.
2024-07-243 citations
Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.
Journal of Clinical Oncology2024-06-012 citations
Abstract CT060: Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
Cancer Research2024-04-05
30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study
Blood2023-11-022 citations
Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part
Blood2022-11-1521 citations
676 A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04
Regular and Young Investigator Award Abstracts2022-11-011 citations
678 A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03
Regular and Young Investigator Award Abstracts2022-11-01
433 A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04
Regular and Young Investigator Award Abstracts2021-11-01
439 A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03
Regular and Young Investigator Award Abstracts2021-11-01
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
Journal for ImmunoTherapy of Cancer2021-10-0151 citations
ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies
Blood2020-11-045 citations